Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board authorizes stock repurchase program of up to $100 million Reaffirms cash runway guidance through the second half of 2028 NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today provided an update on its collaboration with Pfizer Inc. ...

In a previous bearish thesis on Pfizer Inc. (NYSE: PFE ), I recommended selling PFE stock. And it proved to be the right call because since early June, the company has massively underperformedI am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and internationally.In recent years, I have developed a keen ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Pfizer Inc. is one of them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to advance innovative medicines and vaccines across oncology, immunology, rare diseases, and more. The company gained worldwide recognition for its COVID-19 vaccine developed with BioNTech, a major contributor to pandemic response efforts. A key recent development is the positive Phase 3 topline data for Pfizer Inc. (NYSE:PFE ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) announced clinical trial data to reaffirm the effectiveness and safety of their messenger RNA-based COVID shots on Tuesday after President Donald Trump called on the vaccine makers to justify their success earlier this month. New ...

投资逻辑： 特应性皮炎以瘙痒作为重要标志，患者人群众多，疾病负担较重。特应性皮炎（AD）是一种慢性、复发性、炎症性皮 肤病，其特点为：反复发作、病程迁延，患者往往有剧烈瘙痒。影响日常生活，患者就诊意愿强烈，亟需疗效优异、 安全性良好的药物。AD 患者人数众多，全球约 6~7 亿患者、国内约 6700 万患者，未满足需求巨大。 近年来小分子和生物制剂逐步上市，AD 治疗迈入新阶段。传统疗法（如糖皮质激素、TCI 等）安全性不佳，近十年来 生物制剂和小分子靶向药等新兴产品逐渐涌现，目前新兴疗法上市产品不多，全球范围内约十余款不同作用机制的生 物制剂和小分子靶向药物获批用于治疗 AD，包括 JAK、IL-4R、IL-13 等靶点。 小分子 JAK 抑制剂疗效优异，但存在潜在安全性问题，TYK2 有望成为小分子新选择。AD 的小分子药物主要以 JAK 抑 制剂为主，目前已上市的获批 AD 适应症的包括乌帕替尼、艾玛昔替尼等，但以乌帕替尼为代表的多款 JAK 抑制剂均 被 FDA 添加黑框警告，在临床运用中也需要进行监测/评估，安全性存在一定风险。TYK2 作为 JAK 激酶家族的一员， 与 JAK1-3 家族成员参与 ...

A good stock is an even better buy when it's on sale, even if your primary goal is immediate and reliable income.Need investment income? Dividend stocks are an obvious option to consider. If you're looking for one you can comfortably buy and hold forever, however, the matter becomes a bit more complicated. "Forever" is a long time, after all -- the underlying company needs to be one you're confident can continue performing well into an unforeseeable future. Not every organization is built with this sort of ...

Overall, Wall Street rates NEE stock as a “Moderate Buy.” Of the 21 analysts that cover the stock, 12 rate it a “Strong Buy,” eight suggest a “Hold,” and one suggests a “Strong Sell.” Based on the average target price of $82.17, the stock has an upside potential of 15.6% from current levels. Its Street-high estimate of $97 further implies NEE stock can go as high as 36.5% in the next 12 months.It pays a dividend yield of 3.1%, compared to the utilities sector average of 3.7%. NextEra has a strong track reco ...

Key Takeaways Reports suggest COVID-19 vaccines may be linked to 25 child deaths, pressuring major drugmakers.Moderna and BioNTech slid over 7% each, while Pfizer and Novavax fell nearly 4%.CDC advisory panel will review vaccine safety, use and coverage of vaccines on Sept. 18-19.Shares of prominent COVID-19 vaccine makers Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), and Novavax (NVAX) fell on Friday following reports that the Trump administration is preparing to link COVID-19 vaccines to the deaths of 25 ...

LOGIN SUBSCRIBE | FastCo Works advertisement BYÂ Anna-Louise Jackson Listen to this ArticleMore info 0:00 / 0:00 Pharma stocks took a fresh hit on Friday following a report in The Washington Post that the U.S. Food and Drug Administration reportedly plans to link COVID-19 vaccines with the deaths of 25 minors. Moderna shares fell 7.4% Friday to their lowest level since March 2020. The drop brought the drugmaker's year-to-date slump to more than 44%. The Cambridge, Massachusetts-based company is one of two m ...

花旗指出，BioNTech面临下行风险包括：新冠疫苗市场未如预期般稳定，导致收入加速下滑;其ADC(抗 体偶联药物)产品组合的数据未能证明耐久性，从而危及加速或传统审批的可能性;免疫肿瘤产品组合的 OS(总生存期)数据未能证明优于当前治疗标准;FixVac和iNEST平台未能产出有说服力的数据。 智通财经APP获悉，上周五有报道称，特朗普政府卫生官员计划在本周向美国疾病控制与预防中心 (CDC)下属的一个关键疫苗咨询委员会提出新冠疫苗与25名儿童死亡案例相关的主张。据报道，相关主 张包含在特朗普政府卫生官员计划在本周向免疫实践咨询委员会(ACIP)提交的报告中。该委员会在确定 疫苗获取方面发挥着关键作用，因为它审查免疫数据，并就谁有资格接种疫苗以及保险公司是否应该为 他们提供保险等提出建议。 受此消息影响，美股生物科技股上周五全线重挫，研发新冠疫苗的BioNTech(BNTX.US)收跌7.26%，其 新冠疫苗研发合作方辉瑞(PFE.US)收跌3.98%，同样研发新冠疫苗的Moderna(MRNA.US)和诺瓦瓦克斯 医药(NVAX.US)则分别收跌7.40%和3.62%。 对此，花旗发布研报称，相关生物科技 ...